JP2022536223A5 - - Google Patents

Info

Publication number
JP2022536223A5
JP2022536223A5 JP2021524012A JP2021524012A JP2022536223A5 JP 2022536223 A5 JP2022536223 A5 JP 2022536223A5 JP 2021524012 A JP2021524012 A JP 2021524012A JP 2021524012 A JP2021524012 A JP 2021524012A JP 2022536223 A5 JP2022536223 A5 JP 2022536223A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
aqueous extract
azadirachta indica
daily dose
Prior art date
Application number
JP2021524012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536223A (ja
JPWO2020097014A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059774 external-priority patent/WO2020097014A1/en
Publication of JP2022536223A publication Critical patent/JP2022536223A/ja
Publication of JP2022536223A5 publication Critical patent/JP2022536223A5/ja
Publication of JPWO2020097014A5 publication Critical patent/JPWO2020097014A5/ja
Pending legal-status Critical Current

Links

JP2021524012A 2018-11-05 2019-11-05 ニーム抽出物並びにウロリチンa及びbの相乗作用組み合わせの抗糖尿病活性 Pending JP2022536223A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841041788 2018-11-05
PCT/US2019/059774 WO2020097014A1 (en) 2018-11-05 2019-11-05 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b

Publications (3)

Publication Number Publication Date
JP2022536223A JP2022536223A (ja) 2022-08-15
JP2022536223A5 true JP2022536223A5 (https=) 2022-09-05
JPWO2020097014A5 JPWO2020097014A5 (https=) 2022-09-05

Family

ID=70460249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524012A Pending JP2022536223A (ja) 2018-11-05 2019-11-05 ニーム抽出物並びにウロリチンa及びbの相乗作用組み合わせの抗糖尿病活性

Country Status (10)

Country Link
US (1) US20200138892A1 (https=)
EP (1) EP3876968A4 (https=)
JP (1) JP2022536223A (https=)
KR (1) KR20210096121A (https=)
CN (1) CN113226347A (https=)
AU (1) AU2019377432A1 (https=)
BR (1) BR112021008725A2 (https=)
CA (1) CA3118926A1 (https=)
MX (1) MX2021005246A (https=)
WO (1) WO2020097014A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098228A1 (en) * 2020-09-28 2022-03-31 Natreon, Inc. Methods and compositions for improving the immune system and providing immuno-protection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP2005325025A (ja) * 2004-05-12 2005-11-24 Green Kanpo Seiyaku Kk 糖尿病予防・治療組成物
WO2006030426A1 (en) * 2004-09-13 2006-03-23 Amcod Limited Herbal compositions for treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2012530723A5 (https=)
EP3132798B1 (en) Use of composition containing iron (ii) amino acid chelate in preparing drug for regulating and controlling fat metabolism
Demiroren et al. A comparison of the effects of thymoquinone, silymarin and N-acetylcysteine in an experimental hepatotoxicity
CN110099690B (zh) 适于非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎和/或肝脂肪变性的治疗的复方制剂
Mana et al. Therapeutic application of berberine: a consolidated review
JP6364129B2 (ja) 糖尿病の改善に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用
JP2022536223A5 (https=)
JP2021502379A5 (https=)
TW201536300A (zh) 肝臟機能及/或胰臟機能之改善劑
CN106038695B (zh) 鳄梨萃取物、鳄梨醇b及(2r,4r)-1,2,4-三羟基十七碳-16-炔的用途,以及包含鳄梨萃取物的保健食品
TWI793058B (zh) 疾病行為症狀改善劑
JPWO2020097014A5 (https=)
Younis et al. S‐Allyl‐Mercapto‐Captopril: A novel compound in the treatment of cohen‐rosenthal diabetic hypertensive rats
CN106822152B (zh) 一种药物组合物及其应用
Khan et al. Ameliorating effect of Semecarpus anacardium Linn. nut milk extract on altered glucose metabolism in high fat diet STZ induced type 2 diabetic rats
CN103690922A (zh) 一种治疗多囊卵巢综合征的中药组合物及应用
CN104784192B (zh) 蚌肉寡糖在制备降血糖药物中的应用及其制备方法
Maity et al. A clinical comparative study to evaluate the efficacy and safety of Liv. 52 DS tablets in Non-Alcoholic Steatohepatitis (NASH)
WO2018155525A1 (ja) 抗炎症剤
WO2004006946A1 (en) Composition comprising the crude extract of the fruit of morus alba l having neuro-protective activity
TWI615146B (zh) 南洋山蘇水萃物的用途
JP6563375B2 (ja) 腎症治療剤
US11058718B2 (en) Method for treating non-alcoholic steatohepatitis (NASH) with the combination of polaprezinc and sodium selenite
US20200163971A1 (en) Imeglimin for preventing and/or treating hepatocellular carcinoma
TWI624264B (zh) 南洋山蘇水萃物的用途